May 27, 2020
Enrollment Begins in ACTIVATE I Study of Alucent NVS Vessel Restoration System
May 27, 2020—Alucent Biomedical Inc. announced that it has enrolled the first two patients in ACTIVATE I, a phase 1 clinical trial to evaluate the safety and efficacy of its Natural Vascular Scaffolding (NVS) technology for the treatment of peripheral artery disease (PAD) of the lower extremities.
The trial will enroll up to 15 patients at five centers. The first two patients in the ACTIVATE study were enrolled by Christopher Metzger, MD, and his team at Ballad Health Wellmont Holston Valley Medical Center in Kingsport, Tennessee. Other centers include the Cardiovascular Institute of the South in Houma, Louisiana, and Midwest Cardiovascular Research Foundation in Davenport, Iowa.
According to the company, the Alucent NVS vessel restoration system with photoactivated linking combines standard angioplasty with linking of the structural proteins in the wall of a blood vessel. The intervention is designed to deliver immediate restoration of the vessel’s lumen and sustained improvement of blood flow, without the introduction of a foreign implant, such as a metallic stent, into the patient’s body.
“Delivering vessel patency without implants would be a first in medical technology for PAD and has the potential to dramatically improve the level of care vascular interventionalists can provide patients,” commented Dr. Metzger in the company’s announcement. “Being a pioneer in evaluating this technology is an honor.”